Minovia Therapeutics to go public via SPAC merger with Launch One Acquisition in a $239.7m deal.

Minovia Therapeutics, a clinical-stage biotechnology company, agreed to go public via SPAC merger with Launch One Acquisition, a blank check company, in a $239.7m deal. “Minovia is pioneering a new category of mitochondrial therapy that targets the root cause of disease and aging — mitochondrial failure. Our research has already demonstrated durable safety and life-changing impact in patients, including children with genetic mitochondrial disease and older adults with hematologic and kidney dysfunction. Supported by clinical data, FDA Fast Track Designation, and a clear path to a pivotal trial, we believe our MAT platform is uniquely positioned to drive value across both rare disease and the fast-growing longevity market,” Natalie Yivgi-Ohana, Minovia Co-Founder and CEO.